Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Louis Preston Garrison

Louis Preston Garrison

An American health economist

All edits

Edits on 26 Apr, 2022
Vitold River
Vitold River edited on 26 Apr, 2022
Edits made to:
Infobox (+5 properties)
Infobox
Citizenship
Educated at
Nationality
Edits on 6 Feb, 2022
Vitold River
Vitold River edited on 6 Feb, 2022
Edits made to:
Infobox (+2 properties)
Topic thumbnail

Louis Preston Garrison

An American health economist

Infobox
Birthdate
June 22, 1950
Birthplace
Vitold River
Vitold River edited on 6 Feb, 2022
Edits made to:
Description (+28 characters)
Article (+1 images) (+3772 characters)
Topic thumbnail

Louis Preston Garrison

An American health economist

Article

Louis Preston Garrison Jr. is an American health economist who has made significant contributions to pharmacoeconomics, pharmacogenomics and personalized medicine, regulatory benefit-risk analysis, insurance, pricing, reimbursement and risk-sharing agreements. He also made numerous contributions on the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer.

Garrison received his B.A. in Economics at Indiana University and his Ph.D. in Economics at Stanford University. During his doctoral training, Garrison was mentored by Victor Fuchs, who is considered "the dean of health economists."

Garrison served as the president of the International Society for Pharmacoeconomics and Outcomes Research (2016-2017) and is Professor Emeritus at the University of Washington School of Pharmacy. Garrison’s career began with 13 years in non-profit health policy research at the Battelle Memorial Institute Human Affairs Research Centers (Seattle), and at the Project HOPE Center for Health Affairs (Virginia), where he was the Director from 1989-1992. Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Hoffmann-La Roche Pharmaceuticals, and was based in Basel, Switzerland. He then joined the faculty at the University of Washington School of Pharmacy in 2004 until his retirement in 2017.

Incentives to pharmaceutical innovation

Garrison argued that a major challenge to pharmaceutical innovation has been the misalignment of incentives. He further argued that the global product life cycle of oncology medications depended in large part to monopoly power associated with time-limited patent protection given by the Food and Drug Administration. Garrison highlighted that value is a dynamic and moving target and that pharmaceutical pricing should reward innovation based on the value created. Inflexible or fixed pricing schemes do not capture the dynamic value of pharmaceuticals, especially when considering the product life cycle.

Value of personalized medicine

The advent of personalized medicine prompted discussion on its value and reimbursement decision. Garrison and MJ Finley Austin used a standard insure-payer reimbursement framework to identify that health systems reforms are necessary to develop economic incentives for personalized medicine. Garrison believed that a global perspective is necessary to share the cost of innovative medicines, which will result in dynamic efficiency and global public goods.

Risk sharing agreements

Garrison also evaluated the use of Risk Sharing Agreements (RSA) between pharmaceutical companies and health care payers. RSAs are contracts between pharmaceutical companies and health care payers that link coverage reimbursement to pharmaceutical performance. Performance can be defined as financial-based and outcomes-based. Financial-based RSA has reimbursements tied to the market share and utilization of pharmaceutical. Whereas, outcomes-based RSA has reimbursements based on the drug's clinical/health outcomes. Garrison and colleagues reported that US health care payers expressed interest in financial-based RSA but were reluctant to implement outcomes-based RSA due to a lack of confidence.

Awards and recognition

In 2017, Garrison was selected as part of the PharmVOICE 100. Garrison was also honored by being inducted to New Albany High School Hall of Fame (2017), and being honored for his life-time achievements at the Pharmaceutical Outcomes Research and Policy Program 20th Anniversary Research Symposium hosted by University of Washington School of Pharmacy (2016).

Vitold River"Created via: Web app"
Vitold River created this topic on 6 Feb, 2022
Edits made to:
Infobox (+1 properties)
Topic thumbnail

 Louis Preston Garrison

An American health economist

Infobox
Is a
Golden logo
By using this site, you agree to our Terms & Conditions.